Pompe disease therapy wins orphan drug status for BioMarin
BioMarin Pharmaceutical Inc. has received orphan drug status for an investigational enzyme replacement therapy to treat Pompe disease that was developed by ZyStor Therapeutics in Milwaukee, Wisconsin. Just two weeks ago, BioMarin bought ZyStor for $22 million in cash.